BSN: Successful Investigational New Drug application (IND) Review for Intravenous CP-4126

What's My Rank?
      What's My Popularity Score?
      In My Orgs?
      In My Specialities?
      In My Geography?
      In My Age?

My Mentors, Collaborators,
Associates, Peers, Buddies

Keep Me Up To Date
Specialty, Keyword,
Geography

People Making News

Latest Research From
Meetings

Recent Postings

People of Consequence (40156)

1. Richard M. Satava
University of Washington
2. Adam P Dicker
Thomas Jefferson University
3. Lena Specht
Copenhagen University
4. Richard G. Pestell
Kimmel Cancer Center
5. Warren M. Jackman
University of Oklahoma

Orgs of Consequence (10409)

1. University of California, Davis
2. Harvard University
3. Mayo Clinic
4. National Institutes of Health, Chemical Genomics Centre
5. M. D. Anderson Cancer Center

Terms of Consequence

1. Cells
2. Cancer
3. Genetics
4. Molecular
5. Proteins

Successful Investigational New Drug application (IND) Review for Intravenous CP-4126

Friday, July 3

Clavis Pharma ASA (OSE: CLAVIS) announces today that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Intravenous CP-4126. Intravenous CP-4126 is in development as a new, first-line treatment for pancreatic cancer and the phase II program has already been initiated in Europe.

http://www.ad-hoc-news.de/cp-4126-successful-investigational-new-drug-application--/de/Unternehmensnachrichten/20319744

Comments

BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.

Successful Investigational New Drug application (IND) Review for Intravenous CP-4126

Comments

Add Comment